Log In
BCIQ
Print this Print this
 

MCLA-145

  Manage Alerts
Collapse Summary General Information
Company Merus N.V.
DescriptionADCC-enhanced human common light chain bispecific IgG1 antibody that combines an overexpressed tumor target with an immunomodulatory target involved in checkpoint inhibition
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Mechanism of ActionAntibody; Antibody dependent cellular cytotoxicity (ADCC)
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today